Head to Head Contrast: Oncolytics Biotech (ONCY) vs. Puma Biotechnology (PBYI)

Oncolytics Biotech (NASDAQ:ONCY) and Puma Biotechnology (NASDAQ:PBYI) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, dividends, risk, institutional ownership, valuation, analyst recommendations and earnings.

Insider & Institutional Ownership

0.9% of Oncolytics Biotech shares are owned by institutional investors. Comparatively, 91.9% of Puma Biotechnology shares are owned by institutional investors. 0.1% of Oncolytics Biotech shares are owned by insiders. Comparatively, 21.5% of Puma Biotechnology shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Oncolytics Biotech and Puma Biotechnology’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Oncolytics Biotech N/A -219.88% -100.15%
Puma Biotechnology -45.22% -258.02% -51.18%

Earnings & Valuation

This table compares Oncolytics Biotech and Puma Biotechnology’s top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Oncolytics Biotech N/A N/A -$13.14 million ($0.82) -2.37
Puma Biotechnology $251.00 million 5.12 -$113.57 million ($2.99) -11.17

Oncolytics Biotech has higher earnings, but lower revenue than Puma Biotechnology. Puma Biotechnology is trading at a lower price-to-earnings ratio than Oncolytics Biotech, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Oncolytics Biotech and Puma Biotechnology, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Oncolytics Biotech 0 0 2 0 3.00
Puma Biotechnology 3 5 4 0 2.08

Puma Biotechnology has a consensus target price of $52.20, indicating a potential upside of 56.24%. Given Puma Biotechnology’s higher probable upside, analysts clearly believe Puma Biotechnology is more favorable than Oncolytics Biotech.

Volatility & Risk

Oncolytics Biotech has a beta of 2.21, indicating that its share price is 121% more volatile than the S&P 500. Comparatively, Puma Biotechnology has a beta of 0.7, indicating that its share price is 30% less volatile than the S&P 500.

Summary

Oncolytics Biotech beats Puma Biotechnology on 7 of the 13 factors compared between the two stocks.

About Oncolytics Biotech

Oncolytics Biotech Inc., a development stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing REOLYSIN, an immuno-oncology viral-agent that comprises three programs: chemotherapy combinations to trigger selective tumor lysis; immune modulator combinations to facilitate innate immune responses; and immuno-therapy combinations to produce adaptive immune responses. It has a research collaboration with Keck School of Medicine of University of Southern California using pelareorep in combination with Keytruda, Velcade, and dexamethasone to treat multiple myeloma; and a clinical collaboration with SOLTI breast cancer research. Oncolytics Biotech Inc. was founded in 1998 and is headquartered in Calgary, Canada.

About Puma Biotechnology

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care. Its drug candidates include PB272 neratinib (oral) for the treatment of early stage breast cancer, metastatic breast cancer, non-small cell lung cancer, HER2 mutation-positive solid tumors, and HER2-mutated non-amplified breast cancer; and PB272 neratinib (intravenous). The company also develops PB357, an orally administered agent that is an irreversible tyrosine kinase inhibitor that blocks signal transduction through the epidermal growth factor receptors, HER1, HER2, and HER4. It has a license agreement with Pfizer, Inc. for the development, manufacture, and commercialization of PB272 neratinib (oral), PB272 neratinib (intravenous), PB357, and certain related compounds. Puma Biotechnology, Inc. was founded in 2010 and is headquartered in Los Angeles, California.

Receive News & Ratings for Oncolytics Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncolytics Biotech and related companies with MarketBeat.com's FREE daily email newsletter.